{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T13:55:40Z","timestamp":1747749340679,"version":"3.38.0"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,14]],"date-time":"2023-11-14T00:00:00Z","timestamp":1699920000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007210","name":"Varian Medical Systems Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007210","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011676","name":"Elekta","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011676","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016226","name":"Accuray Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016226","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002669","name":"Elekta AB","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002669","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ctro.science","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical and Translational Radiation Oncology"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.ctro.2023.100702","type":"journal-article","created":{"date-parts":[[2023,11,17]],"date-time":"2023-11-17T04:51:07Z","timestamp":1700196667000},"page":"100702","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Prospective results for 5-year survival and toxicity of moderately hypofractionated radiotherapy with simultaneous integrated boost (SIB) in (very) high-risk prostate cancer"],"prefix":"10.1016","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3921-9782","authenticated-orcid":false,"given":"Ingrid","family":"Masson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-1969-2286","authenticated-orcid":false,"given":"Laur\u00e8ne","family":"Larriviere","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc-Andr\u00e9","family":"Mah\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7533-2988","authenticated-orcid":false,"given":"David","family":"Azria","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pascal","family":"Pommier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathalie","family":"Mesgouez-Nebout","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe","family":"Giraud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Didier","family":"Peiffert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruno","family":"Chauvet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe","family":"Dudouet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naji","family":"Salem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4952-5572","authenticated-orcid":false,"given":"Georges","family":"No\u00ebl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan","family":"Khalifa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5935-5218","authenticated-orcid":false,"given":"Igor","family":"Latorzeff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7493-4314","authenticated-orcid":false,"given":"Catherine","family":"Gu\u00e9rin-Charbonnel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2094-1708","authenticated-orcid":false,"given":"St\u00e9phane","family":"Supiot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.ctro.2023.100702_b0005","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/j.annonc.2020.06.011","article-title":"Prostate cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"31","author":"Parker","year":"2020","journal-title":"Ann Oncol."},{"issue":"11","key":"10.1016\/j.ctro.2023.100702_b0010","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/S1470-2045(10)70223-0","article-title":"External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study","volume":"11","author":"Bolla","year":"2010","journal-title":"Lancet Oncol"},{"issue":"24","key":"10.1016\/j.ctro.2023.100702_b0015","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1056\/NEJMoa0810095","article-title":"Duration of androgen suppression in the treatment of prostate cancer","volume":"360","author":"Bolla","year":"2009","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.ctro.2023.100702_b0020","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1016\/j.ijrobp.2004.08.047","article-title":"Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma\u2013long-term results of phase III RTOG 85\u201331","volume":"61","author":"Pilepich","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"10.1016\/j.ctro.2023.100702_b0025","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.eururo.2020.09.042","article-title":"EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer\u20142020 update. Part 1: screening, diagnosis, and local treatment with curative intent","volume":"79","author":"Mottet","year":"2021","journal-title":"Eur Urol."},{"issue":"8","key":"10.1016\/j.ctro.2023.100702_b0030","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.2165\/11591500-000000000-00000","article-title":"Pharmacotherapeutic management of locally advanced prostate cancer: current status","volume":"71","author":"Martin","year":"2011","journal-title":"Drugs"},{"issue":"3","key":"10.1016\/j.ctro.2023.100702_b0035","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/j.ijrobp.2012.05.023","article-title":"Long-term survival and toxicity in patients treated with high-dose intensity modulated radiation therapy for localized prostate cancer","volume":"85","author":"Spratt","year":"2013","journal-title":"Int J Radiat Oncol Mars"},{"issue":"7","key":"10.1016\/j.ctro.2023.100702_b0040","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1001\/jamaoncol.2015.2419","article-title":"Dose-escalated radiotherapy for prostate cancer: is the sky the limit?","volume":"1","author":"Gray","year":"2015","journal-title":"JAMA Oncol"},{"issue":"4","key":"10.1016\/j.ctro.2023.100702_b0045","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/S1470-2045(14)70040-3","article-title":"Escalated-dose versus control-dose conformal radiotherapy for prostate cancer: long-term results from the MRC RT01 randomised controlled trial","volume":"15","author":"Dearnaley","year":"2014","journal-title":"Lancet Oncol Avr"},{"issue":"4","key":"10.1016\/j.ctro.2023.100702_b0050","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/j.ijrobp.2010.03.049","article-title":"70 Gy versus 80 Gy in localized prostate cancer: 5-year results of GETUG 06 randomized trial","volume":"80","author":"Beckendorf","year":"2011","journal-title":"Int J Radiat Oncol Juill"},{"issue":"7","key":"10.1016\/j.ctro.2023.100702_b0055","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1200\/JCO.2009.25.8475","article-title":"Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: long-term results from proton radiation oncology group\/American college of radiology 95\u201309","volume":"28","author":"Zietman","year":"2010","journal-title":"J Clin Oncol Mars"},{"issue":"1","key":"10.1016\/j.ctro.2023.100702_b0060","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.ijrobp.2007.06.054","article-title":"Long-term results of the M.D. Anderson randomized dose-escalation trial for prostate cancer","volume":"70","author":"Kuban","year":"2008","journal-title":"Int J Radiat Oncol."},{"issue":"11","key":"10.1016\/j.ctro.2023.100702_b0065","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1016\/S1470-2045(18)30528-X","article-title":"Sequence of hormonal therapy and radiotherapy field size in unfavourable, localised prostate cancer (NRG\/RTOG 9413): long-term results of a randomised, phase 3 trial","volume":"19","author":"Roach","year":"2018","journal-title":"Lancet Oncol"},{"issue":"11","key":"10.1016\/j.ctro.2023.100702_b0070","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1200\/JCO.20.03282","article-title":"Prostate-only versus whole-pelvic radiation therapy in high-risk and very high-risk prostate cancer (POP-RT): outcomes from phase III randomized controlled trial","volume":"39","author":"Murthy","year":"2021","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol."},{"issue":"5","key":"10.1016\/j.ctro.2023.100702_b0075","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1016\/S0360-3016(03)01569-4","article-title":"Assessment of different IMRT boost delivery methods on target coverage and normal-tissue sparing","volume":"57","author":"Dogan","year":"2003","journal-title":"Int J Radiat Oncol D\u00e9c"},{"issue":"4","key":"10.1016\/j.ctro.2023.100702_b0080","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1016\/j.ijrobp.2004.11.034","article-title":"Dosimetric advantages of IMRT simultaneous integrated boost for high-risk prostate cancer","volume":"61","author":"Li","year":"2005","journal-title":"Int J Radiat Oncol Mars"},{"key":"10.1016\/j.ctro.2023.100702_b0085","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.radonc.2021.07.018","article-title":"Elective pelvic nodal irradiation with a simultaneous hypofractionated integrated prostate boost for localized high risk prostate cancer: Long term results from a prospective clinical trial","volume":"163","author":"Glicksman","year":"2021","journal-title":"Radiother Oncol"},{"issue":"2","key":"10.1016\/j.ctro.2023.100702_b0090","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/s41391-018-0034-0","article-title":"Hypofractionated simultaneous integrated boost (IMRT-SIB) with pelvic nodal irradiation and concurrent androgen deprivation therapy for high-risk prostate cancer: results of a prospective phase II trial","volume":"21","author":"Magli","year":"2018","journal-title":"Prostate Cancer Prostatic Dis Juin"},{"issue":"2","key":"10.1016\/j.ctro.2023.100702_b0095","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1097\/COC.0000000000000133","article-title":"Late Toxicity and outcomes in high-risk prostate cancer patients treated with hypofractionated IMRT and long-term androgen suppression treatment","volume":"40","author":"Pervez","year":"2017","journal-title":"Am J Clin Oncol Avr"},{"key":"10.1016\/j.ctro.2023.100702_b0100","doi-asserted-by":"crossref","unstructured":"Koerber SA, Winter E, Katayama S, Slynko A, Haefner MF, Uhl M, et al. Elective Node Irradiation With Integrated Boost to the Prostate Using Helical IMRT\u2013Clinical Outcome of the Prospective PLATIN-1 Trial. Front Oncol [Internet]. 2019 [cit\u00e9 26 oct 2023];9. Disponible sur: https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2019.00751.","DOI":"10.3389\/fonc.2019.00751"},{"issue":"4","key":"10.1016\/j.ctro.2023.100702_b0105","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.prro.2017.01.003","article-title":"Acute and late toxicity in high-risk prostate cancer patients treated with androgen suppression and hypofractionated pelvic radiation therapy","volume":"7","author":"Faria","year":"2017","journal-title":"Pract Radiat Oncol."},{"issue":"6","key":"10.1016\/j.ctro.2023.100702_b0110","doi-asserted-by":"crossref","first-page":"e514","DOI":"10.1016\/j.prro.2020.06.012","article-title":"Long-term results of moderate hypofractionation to prostate and pelvic nodes plus androgen suppression in high-risk prostate cancer","volume":"10","author":"Faria","year":"2020","journal-title":"Pract Radiat Oncol"},{"issue":"2","key":"10.1016\/j.ctro.2023.100702_b0115","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1016\/j.ijrobp.2010.11.003","article-title":"Hypofractionated concomitant intensity-modulated radiotherapy boost for high-risk prostate cancer: late toxicity","volume":"82","author":"Quon","year":"2012","journal-title":"Int J Radiat Oncol F\u00e9vr"},{"issue":"6","key":"10.1016\/j.ctro.2023.100702_b0120","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.3109\/0284186X.2012.748987","article-title":"Efficacy and toxicity of conventionally fractionated pelvic radiation with a hypofractionated simultaneous versus conventionally fractionated sequential boost for patients with high-risk prostate cancer","volume":"52","author":"McDonald","year":"2013","journal-title":"Acta Oncol."},{"issue":"11","key":"10.1016\/j.ctro.2023.100702_b0125","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1007\/s10147-021-02002-x","article-title":"Long-term safety of high-dose whole pelvic IMRT for high-risk localized prostate cancer through 10-year follow-up","volume":"26","author":"Aizawa","year":"2021","journal-title":"Int J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ctro.2023.100702_b0130","doi-asserted-by":"crossref","first-page":"e52","DOI":"10.1016\/j.clon.2021.08.010","article-title":"Moderately hypofractionated radiotherapy and androgen deprivation therapy for high-risk localised prostate cancer: predictors of long-term biochemical control and toxicity","volume":"34","author":"Maulik","year":"2022","journal-title":"Clin Oncol Janv"},{"issue":"1","key":"10.1016\/j.ctro.2023.100702_b0135","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.ijrobp.2010.09.018","article-title":"Phase I trial of pelvic nodal dose escalation with hypofractionated IMRT for high-risk prostate cancer","volume":"82","author":"Adkison","year":"2012","journal-title":"Int J Radiat Oncol Janv"},{"issue":"3","key":"10.1016\/j.ctro.2023.100702_b0140","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.adro.2019.11.007","article-title":"Ten-year results from a phase II study on image guided, intensity modulated radiation therapy with simultaneous integrated boost in high-risk prostate cancer","volume":"5","author":"Ekanger","year":"2020","journal-title":"Adv Radiat Oncol Mai"},{"issue":"5","key":"10.1016\/j.ctro.2023.100702_b0145","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.prro.2021.02.011","article-title":"Clinical outcomes of the CHIRP trial: a phase II prospective randomized trial of conventionally fractionated versus moderately hypofractionated prostate and pelvic nodal radiation therapy in patients with high-risk prostate cancer","volume":"11","author":"Wang","year":"2021","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.ctro.2023.100702_b0150","article-title":"Hypofractionated, dose escalation radiation therapy for high-risk prostate cancer: the safety analysis of the prostate cancer study-5, a groupe de radio-oncologie g\u00e9nito-urinaire de quebec led phase 3 trial","author":"Niazi","year":"2023","journal-title":"Int J Radiat Oncol."},{"issue":"2","key":"10.1016\/j.ctro.2023.100702_b0155","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1007\/s12253-019-00623-2","article-title":"Acute and late toxicity after moderate hypofractionation with simultaneous integrated boost (SIB) radiation therapy for prostate cancer. A single institution, prospective study","volume":"26","author":"Jorgo","year":"2020","journal-title":"Pathol Oncol Res"},{"issue":"19","key":"10.1016\/j.ctro.2023.100702_b0160","doi-asserted-by":"crossref","first-page":"4970","DOI":"10.3390\/cancers13194970","article-title":"Ten year results of extensive nodal radiotherapy and moderately hypofractionated simultaneous integrated boost in unfavorable intermediate-, high-, and very high-risk prostate cancer","volume":"13","author":"Di Muzio","year":"2021","journal-title":"Cancers"},{"issue":"7","key":"10.1016\/j.ctro.2023.100702_b0165","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1007\/s00432-017-2375-9","article-title":"Moderate hypofractionated radiotherapy with volumetric modulated arc therapy and simultaneous integrated boost for pelvic irradiation in prostate cancer","volume":"143","author":"Franzese","year":"2017","journal-title":"J Cancer Res Clin Oncol Juill"},{"key":"10.1016\/j.ctro.2023.100702_b0170","doi-asserted-by":"crossref","unstructured":"Masson I, Bellanger M, Perrocheau G, Mah\u00e9 MA, Azria D, Pommier P, et al. Cost and Toxicity Comparisons of Two IMRT Techniques for Prostate Cancer: A Micro-Costing Study and Weighted Propensity Score Analysis Based on a Prospective Study. Front Oncol [Internet]. 2022 [cit\u00e9 30 juin 2022];11. Disponible sur: https:\/\/www.frontiersin.org\/article\/10.3389\/fonc.2021.781121.","DOI":"10.3389\/fonc.2021.781121"},{"issue":"12","key":"10.1016\/j.ctro.2023.100702_b0175","first-page":"1288","article-title":"NCCN guidelines\u00ae insights: prostate cancer, version 1.2023","volume":"20","author":"Schaeffer","year":"2022","journal-title":"J Natl Compr Cancer Netw JNCCN D\u00e9c"},{"key":"10.1016\/j.ctro.2023.100702_b0180","doi-asserted-by":"crossref","unstructured":"Hodapp N. [The ICRU Report 83: prescribing, recording and reporting photon-beam intensity-modulated radiation therapy (IMRT)]. Strahlenther Onkol Organ Dtsch Rontgengesellschaft Al. janv 2012;188(1):97\u20119.","DOI":"10.1007\/s00066-011-0015-x"},{"issue":"5","key":"10.1016\/j.ctro.2023.100702_b0185","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/j.ijrobp.2022.04.008","article-title":"meta-analysis of elective pelvic nodal irradiation using moderate hypofractionation for high-risk prostate cancer","volume":"113","author":"Viani","year":"2022","journal-title":"Int J Radiat Oncol Ao\u00fbt"},{"issue":"4","key":"10.1016\/j.ctro.2023.100702_b0190","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.3390\/cancers15041288","article-title":"The association between acute and late genitourinary and gastrointestinal toxicities: an analysis of the PACE B study","volume":"15","author":"Ratnakumaran","year":"2023","journal-title":"Cancers Janv"},{"key":"10.1016\/j.ctro.2023.100702_b0195","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/624736","article-title":"Systematic review of the relationship between acute and late gastrointestinal toxicity after radiotherapy for prostate cancer","volume":"2015","author":"Peach","year":"2015","journal-title":"Prostate Cancer"},{"issue":"4","key":"10.1016\/j.ctro.2023.100702_b0200","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/j.ijrobp.2007.11.044","article-title":"Incidence of late rectal and urinary toxicities after three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for localized prostate cancer","volume":"70","author":"Zelefsky","year":"2008","journal-title":"Int J Radiat Oncol Mars"},{"issue":"10323","key":"10.1016\/j.ctro.2023.100702_b0205","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/S0140-6736(21)02437-5","article-title":"Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol","volume":"399","author":"Attard","year":"2022","journal-title":"The Lancet Janv"}],"container-title":["Clinical and Translational Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405630823001271?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405630823001271?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T02:41:18Z","timestamp":1742179278000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405630823001271"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":41,"alternative-id":["S2405630823001271"],"URL":"https:\/\/doi.org\/10.1016\/j.ctro.2023.100702","relation":{},"ISSN":["2405-6308"],"issn-type":[{"type":"print","value":"2405-6308"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prospective results for 5-year survival and toxicity of moderately hypofractionated radiotherapy with simultaneous integrated boost (SIB) in (very) high-risk prostate cancer","name":"articletitle","label":"Article Title"},{"value":"Clinical and Translational Radiation Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctro.2023.100702","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier B.V. on behalf of European Society for Radiotherapy and Oncology.","name":"copyright","label":"Copyright"}],"article-number":"100702"}}